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Abstract
Cryptosporidium parvum and related species are zoonotic intracellular parasites of the intestine.
Cryptosporidium is a leading cause of diarrhea in small children around the world. Infection can
cause severe pathology in children and immunocompromised patients. This waterborne parasite is
resistant to common methods of water treatment and therefore a prominent threat to drinking and
recreation water even in countries with strong water safety systems. The drugs currently used to
combat these organisms are ineffective. Genomic analysis revealed that the parasite relies solely
on inosine-5′-monophosphate dehydrogenase (IMPDH) for the biosynthesis of guanine
nucleotides. Herein, we report a selective urea-based inhibitor of C. parvum IMPDH (CpIMPDH)
identified by high throughput screening. We performed a SAR study of these inhibitors with some
analogues exhibiting high potency (IC50 < 2 nM) against CpIMPDH, excellent selectivity > 1000-
fold versus human IMPDH type 2 and good stability in mouse liver microsomes. A subset of
inhibitors also displayed potent antiparasitic activity in a Toxoplasma gondii model.
Introduction
Cryptosporidium parasites such as C. parvum and C. hominis are major causes of the
‘vicious cycle of diarrhea and malnutrition’ that afflicts the developing world1. This
infection is self-limiting in healthy adult individuals, but can be chronic and fatal in
immunocompromised patients and children under 5 years of age2. Parasite oocysts are
resistant to commonly used methods of water treatment, and contaminated drinking and
recreational water are major sources of host to host transmission3. While cryptosporidiosis is
more prevalent in developing countries4, the developed world also has a significant disease
burden. Fifteen documented Cryptosporidium waterborne outbreaks were reported during
2000 in the USA, resulting in enormous medical expenses5. Since the oocysts can be
obtained with relative ease and the water supply is readily accessed, C. parvum has the
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potential to be used for bio-terrorism. Consequently, it is considered a class B bio-warfare
agent6. Neither vaccines nor the approved drug nitazoxanide are effective treatments for
cryptosporidiosis in immunocompromised patients, so there is an urgent need for new
chemotherapeutic agents.
Genomic analysis revealed that C. parvum and C. hominis rely on the enzyme inosine 5′-
monophosphate dehydrogenase (IMPDH) for the production of guanine nucleotides2b, 7
(Scheme 1; CpIMPDH will be used to denote the parasite enzyme, which is identical in C.
parvum and C. hominis) 8. Remarkably, these parasites appear to have obtained their
IMPDH gene from an ε-proteobacterium by lateral gene transfer9. The bacterial origin of
CpIMPDH and the different kinetic properties of these enzymes compared with their human
counterparts suggested CpIMPDH-selective inhibitors could be obtained10. A high
throughput screen for selective inhibitors yielded an urea-based inhibitor with an IC50 value
of 340 nM against CpIMPDH (Compound 1, Table 1). Herein, we report a SAR study of 1
with respect to CpIMPDH inhibition and antiparasitic activity and optimization of mouse
microsomal stability.
Results and Discussion
High throughput screen
Following our previously described assay protocol 10, we performed a high throughput
screen of 85,000 compounds to identify inhibitors of CpIMPDH. This screen targeted the
NAD site, which is the most highly diverged region of the active site relative to the human
enzymes. This screen yielded 50 compounds that inhibited CpIMPDH but not human
IMPDH type 2 (IC50 > 5 μM). Six of these compounds were urea-based, of which the most
potent was compound 1 (Figure 1) with IC50 of 340 nM. Interestingly, two urea-based
inhibitors of human IMPDHs, merimepodib and AVN944, have entered clinical trials11,
which further encouraged development of this series
Chemistry
Various derivatives of 1 were prepared following the synthetic method outlined in Scheme
2. Ozonolysis followed by reductive work-up with dimethyl sulfide transformed 3-
isopropenyl-α, α-dimethyl benzyl isocyanate 2 into 3-acetyl-α, α-dimethyl benzyl
isocyanate 3 in moderate yield. Upon treating 2 and 3 with substituted anilines 4, the
corresponding ureas 5 and 6 were obtained. The acetyl group on 6 was converted to the
corresponding oxime 7 and methyl oxime 8 in good yields by heating with a slight excess of
hydroxylamine hydrochloride and methoxyamine hydrochloride, respectively, in pyridine.12
Oxime 7 was alkylated in the presence of sodium hydride with 2-chloroethylamine
hydrochloride to give amine derivative 9. Lithium aluminum hydride (LAH) reduction of
acetyl derivative 6 gave alcohol 10. Hydrogenation of isoprenyl derivative 5 with 10%
palladium on carbon yielded the saturated urea derivative 11 in good yield.
Scheme 3 outlines the reaction sequence used for the synthesis of a mono-methyl urea
derivative. 3-(1-Cyanoethyl)benzoic acid, 12, was converted into acetyl derivative 13 using
a step wise process that involved the conversion of the acid to the corresponding acid
chloride followed by treatment with Meldrum’s acid in the presence of base and then
hydrolytic decarboxylation13. Subsequent hydrolysis of nitrile derivative 13 gave substituted
hydratropic acid 14, which was treated with thionyl chloride followed by sodium azide in
water to generate acyl azide 15 that was used without isolation. Acyl azide 15 was heated to
reflux in benzene under a nitrogen atmosphere to generate isocyanate 1614. Finally, the
isocyanate was treated with 4-chloroaniline to give urea derivative 17.
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An analogue of 1 that lacks both methyl groups on the benzylic position was prepared
according to the procedure outlined in Scheme 4. 3-Acetylbenzonitrile, 18, was treated with
ethylene glycol15 to give the ketal protected benzonitrile derivative 19. LAH reduction
generated benzylamine derivative 20, which was subsequently converted to urea 22 in two
steps via the intermediate p-nitrophenyl carbamate 2116. Removal of the ketal was carried
out under acidic conditions to give 23.
A series of carbamate and amide derivatives were prepared using the methods outlined in
Scheme 5. Isocyanate 3 was refluxed with 8N HCl to give benzylamine derivative 24 in
good yield. This material was converted to carbamate 25 by treatment with 4-chlorophenyl
chloroformate in the presence of base. Amine 24 was also converted to amide 26 in good
yield. In addition, 24 was treated with chlorosulfonic acid, followed by exposure to aqueous
potassium nitrite and subsequent decomposition with sulfate buffer (pH = 2.8) to give the
substituted benzyl alcohol 2717. Upon treatment with 4-chlorophenyl isocyanate, this
material was converted to carbamate 28.
Several biphenyl derivatives were prepared using the methods outlined in Scheme 6. 3-
Phenylcyanobenzene, 29, was allowed to react with 3 equivalents of methyl magnesium
bromide in the presence of the Lewis acid catalyst titanium (IV) isopropoxide to give tert-
alkyamine 3018. Biphenylcyclopropylamine 31 was similarly prepared from 29 by treatment
with 2 equivalents of ethyl magnesium bromide and titanium (IV) isopropoxide19. Amines
30, 31 and 32 were converted to corresponding urea derivatives 36, 37 and 38, respectively,
using a two-step procedure via intermediates 33, 34 and 35.
Evaluation of enzyme inhibition
IMPDH activity was assayed by monitoring the production of NADH. The IC50 values
reported in the tables are the average of three independent experiments unless otherwise
noted. Nonspecific protein binding was assessed by measuring IC50 values in presence of
0.05% fatty acid free bovine serum albumin (BSA)20. Our previous experience indicates that
the IC50 in the presence of BSA is the better predictor of antiparasitic activity21.
For the SAR study, initial attempts were made to optimize the anilide substituent. Removal
of the cyclic urea moiety in 1 yielded compound 5a, which demonstrated a slight increase in
CpIMPDH inhibitory activity with an IC50 of 250 nM (Table 1). Replacing the imidazolone
with a 4-ClPh or 4-BrPh increased potency by 16-fold (5b) and 32-fold (5c), respectively. A
similar trend has also been observed with other CpIMPDH inhibitor series22. However,
translocation of the chlorine atom to the 3-position (5d) resulted in a 3-fold loss of activity,
while the 2-chloro derivative (5e) was completely inactive. The electronic nature of the
substituent in the 4-position had little effect on inhibitory activity. For example, an electron
donating methoxy (5f) retained activity comparable to the bromide (5c) with IC50 of 9 nM.
However, sterics did have an effect as illustrated by the 4-tert+butyl (5g) derivative lacking
activity. Introduction of substituents in the 3,4-positions increased activity. For example,
3,4-di-chloro (5h), 4-chloro-3-trifluoromethyl (5i) and a variety of 3-amido-4-chloro (5k, 5l,
and 5m) substituents increased potency by about 2.5 to 10-fold as compared to 5b. Again
the electronic nature of the 3,4-substitents had little effect as exemplified by 4-chloro-3-
methoxy (5j) and the 3,4-methylenedioxy (5n) analogues, although the latter compound
demonstrated significantly weaker activity in the presence of BSA. Given these results,
several fused carbo- and heteroaromatic derivatives were examined. The 2-naphthyl
derivative (5o) retained potent active, while the regioisomer 1-naphthyl was devoid of
activity. However, the inhibitory activity of 5o decreased in presence of BSA. Replacement
of the 2-naphthyl with 6- and 7-quinolyl (5q and 5r) resulted in highly potent compounds
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that were only modestly reduced in the presence of BSA. The 2- and 3-quinolyl analogues
(5t and 5s) were less potent.
Next, the isoprenyl group was examined (Table 2). Saturation of the alkene to the resulting
isopropyl (11) or removal (38) resulted in complete loss of inhibitory activity. Quite
surprisingly, replacement of the alkene with an alcohol (10) resulted in moderate activity
suggesting that polar substituents could be tolerated at this position. Incorporation of the
alkene into a phenyl (36a) retained potent activity. However, transposing the phenyl (36b) to
the para-position resulted in complete loss of inhibitory activity. Given the relative
importance of the sp2-hybridized substituent at the 3-position and moderate tolerance of a
hydrophilic alcohol in 10, replacement of the alkene with a ketone was explored. In three
cases examined (6a-c) good to moderate inhibitory activity was observed.
The SAR of the central portion of 1 was interrogated next (Table 3). First, the importance of
the gem-dimethyl was confirmed. For example, the mono-methyl derivative 17 was less
active compared to 6a and elimination of the methyl groups (23) resulted in complete loss of
activity. Incorporation of the two methyl groups into a cyclopropane (37) was also
detrimental. Several changes to the urea were examined. For example, N-methylation (5u)
of the aniline portion of the urea and replacement of the nitrogen with oxygen (25) or carbon
(26) were deleterious. Replacement of the benzylamine nitrogen with oxygen (28) was better
tolerated, demonstrating only a 2-fold reduction in activity.
Finally, based on the encouraging results obtained with 6a the ketone functional group was
transformed into hydrophilic oximes and O-methyloximes (Table 4). Gratifyingly, the
oximes (7a, 7b, 7c, 7d and 7e) demonstrated excellent CpIMPDH inhibitory potencies, with
IC50 ≤1 nM. Likewise, the O-methyloximes 8a, 8b and 8c proved to be quite active with
IC50 ≤5 nM. O-Ethanolamine 9 also showed promising activity with an IC50 value of 20
nM.
The introduction of hydrophilic groups in place of the isoprenyl also resulted in
improvements in mouse liver microsomal stability, which was a potential liability for 5k and
5r (Table 5). The ketone derivative 6c was very resistant to oxidative degradation in
microsomes. The oximes demonstrated a range of stabilities, with 7c having a t½ of 190 min.
While the O-methyloxime 8a was less stable, the aminoethyleneoxime derivative 9 showed
excellent mouse liver microsomal stability with t1/2 > 2 hours. All of the compounds
examined demonstrated excellent mouse plasma stability.
Toxoplasma gondii is an intracellular parasite closely related to Cryptosporidium that,
unlike C. parvum, can be continuously cultured in hTERT immortalized human foreskin
fibroblasts. We engineered a T. gondii strain (Toxo/CpIMPDH) that relies on CpIMPDH,
and is sensitive to CpIMPDH inhibitors21. In contrast, the wild type T. gondii strain RH
(Toxo/WT) contains a typical eukaryotic IMPDH and is resistant to CpIMPDH inhibitors.
Therefore, Toxo/WT serves as a proxy for host cell toxicity as well as provides important
target validation.
Approximately thirty compounds with good inhibitory activity against CpIMPDH were
tested in the Toxoplasma model. Eleven compounds had EC50 values ≤ 200 nM with
selectivity ≥ 100-fold over Toxo/WT. Gratifyingly, 7b, our best inhibitor in the enzyme
assay, also displayed the best antiparasitic activity with EC50 of 6 nM and 670-fold
selectivity over Toxo/WT. Compounds 7a and 7e are also very promising candidates, with
EC50 values of 10 nM and 58 nM, respectively, and selectivity ≥ 230.
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Conclusion
In this study, the SAR of the CpIMPDH inhibitor 1 was investigated. Initially, the anilide
portion of the molecule was explored. Several derivatives containing 3,4-di-substitution or
3,4-ring fusion were found to significantly increase inhibitory potency. The aniline nitrogen
atom of the urea was necessary for potent activity, while the other nitrogen could be replace
with oxygen. The gem-dimethyl group was also found to be best for CpIMPDH inhibition.
The 3-isopropenyl substituent could be replaced with a number of hydrophobic or
hydrophilic groups, but those with sp2-hybridization (e.g. phenyl, acetyl, oximes, or O-
methyloximes) were best. Eleven compounds displayed potent and selective in vitro
antiparastic activity, including two that also demonstrated good in vitro metabolic stability.
These compounds appear to possess the necessary properties for evaluation in an animal
model of cryptosporidiosis in order to determine the optimal pharmacological profile
necessary for in vivo efficacy.
Experimental Section
Chemistry Materials and Methods
Unless otherwise noted, all reagents and solvents were purchased from commercial sources
and used without further purification. All reactions were performed under nitrogen
atmosphere unless otherwise noted. The NMR spectra were obtained using a 400 MHz
spectrometer. All 1H NMR spectra are reported in δ units ppm and are reference to
tetramethylsilane (TMS) if conducted in CDCl3 or to the central line of the quintet at 2.49
ppm for samples in DMSO-d6. All chemical shift values are also reported with multiplicity,
coupling constants and proton count. All 13C NMR spectra are reported in δ units ppm and
are reference to the central line of the triplet at 77.23 ppm if conducted in CDCl3 or to the
central line of the septet at 39.5 ppm for samples in DMSO-d6. Coupling constants (J
values) are reported in hertz. Column chromatography was carried out on SILICYCLE
SiliaFlash silica gel F60 (40-63 Vm, mesh 230-400). High-resolution mass spectra were
obtained using a Q-Tof Ultima mass spectrometer (University of Illinois Urbana-
Champaign, Urbana, IL 61801). All melting points were taken in glass capillary tubes and
are uncorrected. All test compounds reported in this manuscript had a purity ≥ 95% as
determined by high performance liquid chromatography (HPLC) analyses using an
instrument equipped with a quaternary pump and a Zorbaxρ SB-C8 column (30 × 4.6 mm,
3.5 μm). UV absorption was monitored at λ = 254 nm. The injection volume was 5 VL.
HPLC gradient went from 5 % acetonitrile and 95 % water to 95 % acetonitrile and 5 %
water (both solvents contain 0.1% trifluoroacetic acid) over 1.9 min with a total run time of
2.5 min and a flow rate of 3.0 mL/min.
Synthesis of 3-acetyl-α, α-dimethylbenzyl isocyanate (3)
A solution of 3-isopropenyl-α, α-dimethyl benzyl isocyanate (2.04 g, 10.14 mmol) in
dichloromethane (40 mL) was cooled to -78 oC and then treated with dry ozone in oxygen
until a blue color persist. Excess ozone was flushed off with oxygen. Dimethyl sulfide (0.74
mL, 10.14 mmol) was added to the reaction mixture, which was then stirred overnight at
room temperature. Excess Me2S was removed by evaporated on a water bath placed inside a
fume hood. Water (30 mL) was added to the reaction mixture, which was then extracted
with dichloromethane. The combined organic layers were washed with brine (30 mL) and
dried over anhydrous MgSO4. The mixture was filtered and the filtrate concentrated. The
residue was purified by silica gel column chromatography using ethylacetate/ hexane (1: 10)
as an eluent to furnish 5b (1.19 g, 58%). 1H NMR (CDCl3, 400 MHz) δ 1.76 (s, 6H), 2.63
(s, 3H), 7.47 (t, J = 8 Hz, 1H), 7.67 (dd, J1 = 7.6 Hz, J2 = 2 Hz, 1H), 7.86 (dt, J1 = 7.6 Hz, J2
= 1.2 Hz, 1H), 8.04 (t, J = 2 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 26.9, 33.2, 60.9,
124.2, 127.6, 129.0, 129.4, 137.4, 146.6, 198.1.
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General procedure for the preparation of urea derivatives 5 : Exemplified for the
preparation of 1-(4-chlorophenyl)-3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea (5b)
To a solution of 3-isopropenyl α, α-dimethylbenzyl isocyanate 2 (473 mg, 2.35 mmol) in
dichloromethane (6 mL) at 0 °C was added 4-chloroaniline (300 mg, 2.35 mmol) in
dichloromethane (3 mL). The reaction was stirred until complete consumption of starting
materials. The precipitated product was collected by filtration and washed with
dichloromethane to give 5b (852 mg, 80%). mp 234-236 °C Yield 80 %; 1H NMR (DMSO
+d6, 400 MHz) δ 1.58 (s, 6H), 2.08 (s, 3H), 5.06 (s, 1H), 5.36 (s, 1H), 6.64 (s, 1H), 7.20 (d,
J = 6.4 Hz, 2H), 7.23-7.32 (m, 5H), 7.47 (s, 1H), 8.55 (s, 1H); 13C NMR (DMSO+d6, 100
MHz) δ 22.24, 30.30, 55.0, 113.06, 119.50, 122.35, 123.69, 124.86, 124.95, 128.65, 129.09,
140.11, 140.73, 143.60, 148.95, 154.53; ESI-HRMS for C19H22N2OCl (M+H)+ calcd.
329.1421, found 329.1418.
1-Phenyl-3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea (5a)
mp 188-190 °C; Yield 81%; 1H NMR (DMSO-d6, 400 MHz) δ 1.58 (s, 6H), 2.08 (s, 3H),
5.06 (s, 1H), 5.36 (s, 1H), 6.59 (s, 1H), 6.83 (t, J =7.2 Hz, 1H), 7.15 (t, J = 8 Hz, 2H),
7.24-7.31 (m, 5H), 7.47 (s, 1H), 8.39 (s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 22.25,
30.39, 54.97, 113.05, 118.00, 121.55, 122.36, 123.65, 124.87, 128.64, 129.28, 140.70,
141.12, 143.62, 149.11, 154.71; ESI-HRMS for C19H23N2O (M+H)+ calcd. 295.1810, found
389.1815.
1-(4-Bromophenyl)-3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea (5c)
Yield 78 %; 1H NMR (DMSO-d6, 400 MHz) δ 1.61 (s, 6H), 2.10 (s, 3H), 5.08 (s, 1H), 5.38
(s, 1H), 6.66 (s, 1H), 7.28-7.35 (m, 5H), 7.49 (s, 1H), 8.57 (s, 1H); 13C NMR (DMSO-d6,
100 MHz) δ 22.23, 30.29, 55.07, 112.76, 113.06, 119.96, 122.35, 123.70, 124.85, 128.65,
131.97, 140.53, 140.74, 143.62, 148.94, 154.50; ESI-HRMS for C19H22N2OBr (M+H)+
calcd. 373.0915, found 373.0915.
1-(3-Chlorophenyl)-3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea (5d)
Yield 83 %; 1H NMR (DMSO-d6, 400 MHz) δ 1.59 (s, 6H), 2.09 (s, 3H), 5.07 (s, 1H), 5.37
(s, 1H), 6.70 (s, 1H), 6.89 (d, J = 7.6 Hz, 1H), 7.05 (d, J = 7.6 Hz 1H), 7.19 (t, J = 8 Hz ,1H),
7.28-7.30 (m, 3H), 7.48 (s, 1H), 7.60 (s, 1H), 8.63 (s,1H) ; 13C NMR (DMSO-d6, 100 MHz)
δ 22.23, 30.26, 55.08, 113.08, 116.41, 117.32, 121.15, 122.32, 123.71, 124.83, 128.67,
130.88, 133.78, 140.74, 142.63, 143.60, 148.88, 154.44; ESI-HRMS for C19H22N2OCl (M
+H)+ calcd. 329.1421, found 329.1430.
1-(2-Chlorophenyl)-3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea (5e)
Yield 65 %; 1H NMR (DMSO-d6, 400 MHz) δ 1.62 (s, 6H), 2.1 (s, 3H), 5.08 (s, 1H), 5.38
(s, 1H), 6.91 (t, J = 7.2 Hz, 1H), 7.16 (t, J = 8.8 Hz, 1H), 7.30-7.32 (m, 3H), 7.37 (dd, 1H, J
= 7.2 Hz, J2 = 3.2 Hz), 7.49-7.52 (m, 2H), 8.02 (dd, J1= 7.8 Hz, J = 2 Hz), 8.09 (d, J = 2 Hz,
1H); 13 2 C NMR (DMSO-d6, 100 MHz) δ 22.22, 30.29, 55.17, 113.06, 121.08, 121.50,
122.32, 122.86, 123.69, 124.86, 127.99, 128.68, 129.67, 137.38, 140.71, 143.59, 148.92,
154.22; ESI-HRMS for C19H22N2OCl (M+H)+ calcd. 329.1421, found 329.1430.
1-(4-Methoxyphenyl)-3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea (5f)
Yield 85%; 1H NMR (DMSO-d6, 400 MHz) δ 1.59 (s, 6H), 2.10 (s, 3H), 3.66 (s, 3H), 5.08
(s, 1H), 5.37 (s, 1H), 6.50 (s, 1H), 6.77 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H),
7.29-7.31 (m, 3H), 7.49 (s, 1H), 8.22 (s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 22.23,
30.46, 54.92, 55.74, 113.01, 114.47, 119.64, 122.36, 123.60, 124.88, 128.61, 134.28,
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140.67, 143.63, 149.25, 154.40, 154.95; ESI-HRMS for C20H25N2O2 (M+H)+ calcd.
325.1916, found 325.1919.
1-(4-(tert-Butyl)phenyl)-3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea-(5g)
Yield 87%; 1H NMR (DMSO-d6, 400 MHz) δ 1.20 (s, 9H), 1.58 (s, 6H), 2.09 (s, 3H), 5.06
(s, 1H), 5.36 (s, 1H), 6.54 (s, 1H), 7.15-7.19 (m, 4H), 7.27-7.30 (m, 3H), 7.48 (s, 1H), 8.31
(s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 22.25, 30.45, 31.93, 34.42, 54.95, 113.02,
117.88, 122.37, 123.62, 124.87, 125.84, 128.62, 138.52, 140.70, 143.63, 143.79, 149.19,
154.82; ESI-HRMS for C23H31N2O (M+H)+ calcd. 351.2436, found 3512433.
1-(3,4-Dichlorophenyl)-3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea (5h)
mp 198-200 °C Yield 80 %; 1H NMR (DMSO-d6, 400 MHz) δ 1.61 (s, 6H), 2.10 (s, 3H),
5.09 (s, 1H), 5.38 (s, 1H), 6.79 (s, 1H), 7.13 (t, J = 4.8 Hz, 1H), 7.31 - 7.34 (m, 3H), 7.42 (d,
J =7.6 Hz ,1H), 7.49 (s, 1H), 7.79 (s, 1H), 8.79 (s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ
22.23, 30.21, 55.14, 113.03, 118.13, 118.95, 122.31, 123.75, 124.82, 128.69, 131.07,
131.58, 140.76, 141.31, 141.34, 143.58, 148.79, 154.33; ESI-HRMS for C19H21N2OCl2 (M
+H)+ calcd. 363.1031, found 363.1029.
1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea (5i)
Yield 82%; 1H NMR (DMSO-d6, 400 MHz) δ 1.61 (s, 6H), 2.10 (s, 3H), 5.09 (s, 1H), 5.38
(s, 1H), 6.81 (s, 1H), 7.30-7.33 (m, 3H), 7.42-7.44 (m, 1H), 7.49-7.53 (m, 2H), 8.01 (s,
1H); 13C NMR (DMSO-d6, 100 MHz) δ 22.22, 30.22, 55.20, 113.11, 116.35, 116.40,
121.90, 122.12, 122.30, 122.78, 123.77, 124.81, 128.70, 132.50, 140.66, 140.78, 143.58,
148.73, 154.36; ESI-HRMS for C20H21N2OClF3 (M+H)+ calcd. 397.1295, found 397.1296.
1-(4-Chloro-3-methoxyphenyl)-3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea (5j)
Yield 89%; 1H NMR (DMSO-d6, 400 MHz) δ 1.59 (s, 6H), 2.09 (s, 3H), 3.73 (s, 3H), 5.07
(s, 1H), 5.37 (s, 1H), 6.66 (s, 1H), 6.72 (d, J = 8.8 Hz, 1H), 7.18 (d, J = 8.8 Hz,1H),
7.28-7.32 (m, 4H), 7.48 (s, 1H), 8.59 (s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 22.23,
30.34, 55.03, 56.28, 102.50, 110.59, 112.95, 113.10, 122.33, 123.72, 124.85, 128.70,
130.16, 140.75, 141.47, 143.59, 148.97, 154.53, 155.10; ESI-HRMS for C20H24N2O2Cl (M
+H)+ calcd. 359.1529, found 359.1532.
2-Chloro-5-(3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)ureido)benzamide (5k)
Yield 72 %; 1H NMR (DMSO-d6, 400 MHz) δ 1.57 (s, 6H), 2.06 (s, 3H), 5.04 (s, 1H), 5.34
(s, 1H), 6.65 (s, 1H), 7.22 - 7.27 (m, 5H), 7.44-7.48 (m, 3H), 7.75 (s, 1H), 8.61 (s,1H) ; 13C
NMR (DMSO-d6, 100 MHz) δ 22.23, 30.27, 55.08, 113.08, 117.61, 119.67, 121.36, 122.31,
123.71, 124.82, 128.66, 130.33, 137.89, 139.95, 140.73, 143.59, 148.89, 154.45, 168.85;
ESI-HRMS for C20H23N3O2Cl (M+H)+ calcd. 372.1479, found 372.1485.
2-Chloro-N-methyl-5-(3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)ureido)benzamide (5l)
Yield 72%; 1H NMR (CDCl3, 400 MHz) δ 1.64 (s, 6H), 2.17 (s, 3H), 2.89 (d, J = 4.8 Hz,
3H), 5.05 (s, 1H), 5.32 (s, 1H), 5.97 (s, 1H,), 6.61 (d, J = 4.4 Hz, 1H), 7.10-7.13 (m, 2H),
7.27-7.31 (m, 2H), 7.49 −7.51 (m, 3H), 7.81 (s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ
22.25, 26.56, 30.26, 55.08, 113.09, 117.76, 119.75, 121.57, 122.31, 123.71, 124.82, 128.66,
130.32, 137.80, 140.01, 140.74, 143.59, 148.90, 167.41, 189.22; ESI-HRMS for
C21H25N3O2Cl (M+H)+ cacld. 386.1635, found 386.1639.
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2-Chloro-N,N-dimethyl-5-(3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)ureido)benzamide (5m)
Yield 72%; 1H NMR (CDCl3, 400 MHz) δ 1.66 (s, 6H), 2.13 (s, 3H), 2.86 (s, 3H), 3.07 (s,
3H), 5.05 (s, 1H), 5.33 (s, 1H), 6.02 (s, 1H,), 6.88 (d, J = 2.4 Hz, 1H), 7.11 (d, J = 8.8Hz,
2H), 7.25-7.35 (m, 4H), 7.50 (s, 1H), 8.01 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 22.17,
29.89, 30.16, 34.94, 38.49, 55.13, 112.51, 116.93, 120.92, 121.29, 122.18, 123.81, 124.24,
128.33, 129.97, 135.15, 139.83, 141.27, 143.81, 147.93, 154.48, 169.80; ESI-HRMS for
C22H27N3O2Cl (M+H)+ calcd. 400.1792, found 400.1787.
1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl) 3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea (5n)
Yield 75%; 1H NMR (DMSO-d6, 400 MHz) δ 1.59 (s, 6H), 2.10 (s, 3H), 4.15 (d, J = 7.6 Hz,
4H), 5.08 (s, 1H), 5.37 (s, 1H), 6.50 (s, 1H), 6.67 (d, J = 8.4 Hz, 2H), 6.97 (s, 1H), 7.29-7.31
(m, 3H), 7.49 (s, 1H), 8.22 (s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 22.22, 30.42, 54.93,
64.44, 64.82, 107.22, 111.36, 113.0, 117.31, 122.35, 123.60, 124.85, 128.60, 134.89,
138.31, 140.68, 143.62, 143.65, 149.17, 154.81; ESI-HRMS for C21H25N2O3 (M+H)+
calcd. 353.1865, found 353.186.
1-(Naphthalen-2-yl)-3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea (5o)
mp 201-203 °C; Yield 75%; 1H NMR (DMSO-d6, 400 MHz) δ 1.64 (s, 6H), 2.11 (s, 3H),
5.08 (s, 1H), 5.39 (s, 1H), 6.72 (s, 1H), 7.27-7.39 (m, 6H), 7.53 (d, J = 1.2 Hz, 1H), 7.68 (d,
J = 8 Hz, 1H), 7.75 (d, J = 8.4 Hz, 2H), 7.98 (s, 1H), 8.64 (s, 1H) ; 13C NMR (DMSO-d6,
100 MHz) δ 22.23, 30.35, 55.04, 112.83, 113.06, 119.92, 122.37,123.69, 124.12, 124.90,
126.85, 127.38, 128.01, 128.67, 128.89, 129.29, 134.49, 138.73, 140.75, 143.63, 149.09,
154.78; ESI-HRMS for C23H25N2O (M+H)+ calcd. 345.1967, found 345.1964.
1-(Naphthalen-1-yl)-3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea (5p)
mp 206-208 °C; Yield 75%; 1H NMR (DMSO-d6, 400 MHz) δ 1.66 (s, 6H), 2.10 (s, 3H),
5.08 (s, 1H), 5.39 (s, 1H), 7.13 (s, 1H), 7.29-7.38 (m, 4H), 7.50-7.55 (m, 4H), 7.90 (d, J =
7.6 Hz, 1H), 7.87 (d, J = 8 Hz, 1H), 8.10 (d, J = 8.4 Hz, 1H), 8.54 (s, 1H); 13C NMR
(DMSO-d6, 100 MHz) δ 22.24, 30.42, 55.16, 113.05, 116.51, 121.79, 122.40, 123.68,
124.92, 125.80, 126.01, 126.36, 126.52, 128.68, 129.06, 134.33, 135.77, 140.74, 143.61,
149.15, 155.02; ESI-HRMS for C23H25N2O (M+H)+ calcd. 345.1967, found 345.1976.
1-(2-(3-(Prop-1-en-2-yl)phenyl)propan-2-yl)-3-(quinolin-6-yl)urea (5q)
Yield 81%; 1H NMR (DMSO-d6, 400 MHz) δ 1.65 (s, 6H), 2.11 (s, 3H), 5.08 (s, 1H), 5.39
(s, 1H), 7.10 (s, 1H), 7.29-7.37 (m, 2H), 7.54 (s, 1H), 7.67-7.74 (m, 2H), 8.04 (d, J = 9.2 Hz,
1H), 8.27 (d, J = 2 Hz, 1H), 8.33 (s, 1H), 8.57 (d, J = 8.4 Hz, 1H), 8.87 (d, J = 4 Hz, 1H),
9.39 (s, 1H) ; 13C NMR (DMSO-d6, 100 MHz) δ 22.25, 30.31, 55.14, 112.04, 113.07,
122.37, 122.45, 123.68, 124.87, 125.70, 125.75, 128.65, 130.06, 138.77, 138.79, 140.72,
140.75, 143.58, 145.04, 148.96, 154.68; ESI-HRMS for C22H24N3O (M+H)+ calcd.
346.1919, found 346.1925.
1-(2-(3-(Prop-1-en-2-yl)phenyl)propan-2-yl)-3-(quinolin-7-yl)urea (5r)
Yield 72%; 1H NMR (DMSO-d6, 400 MHz) δ 1.64 (s, 6H), 2.11 (s, 3H), 5.08 (s, 1H), 5.39
(s, 1H), 6.79 (s, 1H), 7.28-7.37 (m, 4H), 7.47-7.53 (m, 2H), 7.80 (d, J = 8.8 Hz, 1H), 8.03 (d,
J = 2 Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 8.75 (dd, J1= 4.4 Hz, J2=1.6 Hz, 1H), 8.85 (s,
1H) ; 13C NMR (DMSO-d6, 100 MHz) δ 22.23, 30.30, 55.16, 113.09, 113.66, 119.69,
120.23, 122.37, 123.73, 124.88, 128.69, 128.98, 136.03, 140.77, 142.06, 143.61, 148.92,
149.48, 151.27, 154.55; ESI-HRMS for C22H24N3O (M+H)+ calcd. 346.1919, found
346.1915.
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1-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)-3-(quinolin-3-yl)urea (5s)
Yield 69%; 1H NMR (DMSO-d6, 400 MHz) δ 1.65 (s, 6H), 2.11 (s, 3H), 5.09 (s, 1H), 5.39
(s, 1H), 6.88 (s, 1H), 7.31-7.38 (m, 3H), 7.49-7.55 (m, 3H), 7.79 (d, J = 7.2 Hz, 1H), 7.88 (d,
J = 7.4 Hz, 1H), 8.41 (s, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.91 (s, 1H); 13C NMR (DMSO-d6,
100 MHz) δ 22.24, 30.25, 55.17, 113.11, 119.44, 122.35, 123.75, 124.89, 127.27, 127.49,
127.81, 128.71, 128.90, 129.10, 134.88, 140.77, 143.60, 143.82, 144.47, 148.88, 154.72;
ESI-HRMS for C22H24N3O (M+H)+ calcd. 346.1919, found 346.1924.
1-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)-3-(quinolin-2-yl)urea (5t)
mp 126-128 °C; Yield 75%; 1H NMR (CDCl3, 400 MHz) δ 1.90 (s, 6H), 2.13 (s, 3H), 5.05
(s, 1H), 5.37 (s, 1H), 6.54 (d, J = 8.8 Hz, 1H), 7.25-7.38 (m, 3H), 7.48 (d, J = 7.6 Hz, 1H),
7.57-7.67 (m, 4H), 7.83 (d, J = 8.8 Hz, 1H), 9.69 (s, 1H), 10.92 (s, 1H); 13C NMR (CDCl3,
100 MHz) δ 22.20, 30.11, 55.62, 113.19, 114.22, 122.47, 123.95, 124.71, 124.84, 124.89,
126.57, 128.42, 128.82, 130.71, 139.03, 140.94, 143.57, 145.55, 148.65, 153.54, 154.10;
ESI-HRMS for C22H24N3O (M+H)+ calcd. 346.1919, found 346.1917.
1-(4-Chlorophenyl)-1-methyl-3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea (5u)
Yield 56%; 1H NMR (DMSO-d6, 400 MHz) δ 1.50 (s, 6H), 2.06 (s, 3H), 3.11 (s, 3H), 5.04
(s, 1H), 5.32 (s, 1H), 6.11 (s, 1H), 7.21-7.25 (m, 5H), 7.34-7.40 (m, 3H); 13C NMR (DMSO-
d6, 100 MHz) δ 22.25, 30.28, 37.49, 55.72, 112.90, 122.26, 123.40, 124.81, 127.92, 128.49,
129.50, 129.58, 140.54, 143.64, 144.18, 149.37, 156.06; ESI-HRMS for C20H24N2OCl (M
+H)+ calcd. 343.1577, found 343.1570.
General procedure for the preparation of urea derivatives 6: Exemplified for the
preparation of 5-(3-(2-(3-acetylphenyl)propan-2-yl)ureido)-2-chlorobenzamide (6c)
To a solution of 3-acetyl α, α dimethyl isocyanate 3 (118 mg, 0.584 mmol) in THF at room
temperature was added 5-amino-2-chlorobenzamide (100 mg, 0.584 mmol). The reaction
was heated to 70 °C for 6 h. Volatiles were removed under reduced pressure and the residue
was purified by column chromatography using methanol/chloroform as eluent to obtain urea
derivative 6c (156 mg, 72%). 1H NMR (DMSO-d6, 400 MHz) δ 1.61 (s, 6H), 2.58 (s, 3H),
6.80 (s, 1H), 7.26 (s, 2H), 7.45-7.52 (m, 3H), 7.66 (d, J = 7.2 Hz, 1H), 7.79-7.83 (m, 2H),
7.94 (s, 1H), 8.68 (s, 1H) ; 13C NMR (DMSO-d6, 100 MHz) δ 27.44, 30.19, 54.89, 117.63,
119.72, 121.43, 124.57, 127.12, 129.11, 130.42, 137.24, 137.89, 139.87, 149.54, 154.40,
168.87, 198.76; ESI-HRMS for C25H16N3O (M+H)+ calcd. 374.1293, found 374.1283.
1-(2-(3-acetylphenyl)propan-2-yl)-3-(4-chlorophenyl)urea (6a)
Yield 85 %; 1H NMR (DMSO-d6, 400 MHz) δ 1.57 (s, 6H), 2.52 (s, 3H), 6.71 (s, 1H), 7.17
(d, J = 9.2 Hz, 2H), 7.29 (d, J = 8.8 Hz, 2H), 7.42 (t, J = 7.6 Hz, 1H), 7.62 (d, J = 7.6 Hz,
1H), 7.77 (d, J = 7.6 Hz, 1H), 7.91 (s, 1H), 8.54 (s, 1H) ; 13C NMR (DMSO-d6, 100 MHz) δ
29.8, 32.6, 57.2, 121.9, 127.0, 127.4, 129.4, 131.5, 131.55, 132.8, 139.7, 142.4, 152.0,
156.9, 201.1; ESI-HRMS for C18H19ClN2O2 (M+H)+ : calcd. 331.1213, found 331.1214..
1-(2-(3-Acetylphenyl)propan-2-yl)-3-(4-chloro-3 (trifluoromethyl)phenyl)urea (6b)
Yield 69 %; 1H NMR (DMSO-d6, 400 MHz) δ 1.62 (s, 6H), 2.51 (s, 3H), 6.91 (s, 1H), 7.42
- 7.53 (m, 3H), 7.68 (d, J = 7.2 Hz, 1H), 7.84 (d, J = 7.2 Hz, 1H), 7.95 (s, 1H), 8.01 (s, 1H),
8.95 (s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 27.45, 30.14, 54.99, 116.36, 116.41,
116.47, 121.96, 122.83, 124.56, 127.17, 129.15, 130.42, 132.50, 137.28, 140.58, 149.37,
154.31, 198.71; ESI-HRMS for C19H19N2O2ClF3 (M+H)+ calcd. 399.1087, found
399.1089.
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General procedure for the preparation of oxime derivatives 7: Exemplified for the
preparation of (E) 2 chloro 5-(3-(2-(3-(1-(hydroxyimino)ethyl)phenyl)propan-2-
yl)ureido)benzamide (7c)
Hydroxylamine hydrochloride (25 mg, 0.362 mmol) was added to a solution of 56 (100 mg,
0.302 mmol) in 3 mL of pyridine. The reaction solution was heated to 90 °C for 2 hours.
The reaction was allowed to cool to room temperature and then the pyridine was removed by
evaporation under reduced pressure. The resulting residue was dissolved in methanol and
purified by column chromatography eluting with methanol/chloroform to obtained 7c (88
mg, 85%). 1H NMR (DMSO-d6, 400 MHz) δ 1.54 (s, 6H), 2.11 (s, 3H), 6.67 (s, 1H), 7.20 -
7.49 (m, 7H), 7.67 (s, 1H), 7.76 (s, 1H), 8.62 (s, 1H), 11.13 (s, 1H); 13C NMR (DMSO-d6,
100 MHz) δ 12.42, 30.27, 54.98, 117.59, 119.67, 121.38, 122.44, 124.21, 125.87, 128.76,
130.35, 137.33, 137.90, 139.96, 148.95, 153.79, 154.39, 168.90; ESI-HRMS for
C19H22N4O3Cl (M+H)+ calcd. 389.1380, found 389.1384.
(E)-1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(2-(3-(1-(hydroxyimino)ethyl)phenyl)propan-2-
yl)urea (7a)
mp 194-196 °C; Yield 71%; 1H NMR (DMSO-d6, 400 MHz) δ 1.61 (s, 6H), 2.15 (s, 3H),
6.82 (s, 1H), 7.34 (d, J = 8 Hz, 1H), 7.39 – 7.46 (m, 3H), 7.52 (d, J = 9.2 Hz, 1H), 7.70 (s,
1H), 8.01 (s, 1H), 8.91(s, 1H), 11.17 (bs, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 12.39,
30.19, 55.07, 116.31, 116.37, 116.42, 121.91, 122.44, 122.76, 124.25, 125.84, 128.78,
132.50, 137.36, 140.64, 149.77, 153.74, 154.29; ESI-HRMS for C19H20N3O2ClF3 (M+H)+
calcd. 414.1196, found 414.1191.
(E)-1-(4-Chloro-3-nitrophenyl)-3-(2-(3-(1-(hydroxyimino)ethyl)phenyl)propan-2-yl)urea (7b)
mp 183-185 °C; Yield 80%; 1H NMR (DMSO-d6, 400 MHz) δ 1.62 (s, 6H), 2.16 (s, 3H),
6.91 (s, 1H), 7.35 (t, J = 8.0 Hz, 1H), 7.35 (t, J = 8.0 Hz, 1H), 7.41-7.47 (m, 3H), 7.58 (d, J =
8.8 Hz, 1H), 7.71 (s, 1H), 8.22 (d, J = 2.4 Hz, 1H), 9.04 (s, 1H), 11.18 (s, 1H); 13C NMR
(DMSO-d6, 100 MHz) δ 12.4, 30.13, 55.12, 113.84, 116.26, 122.42, 122.86, 124.27, 125.84,
128.79, 132.28, 137.36, 141.11, 148.14, 148.67, 153.74, 154.12; ESI-HRMS for
C18H20N4O4Cl (M+H)+ calcd. 391.1173, found 391.1172.
(E)-1-(2-(3-(1-(Hydroxyimino)ethyl)phenyl)propan-2-yl) 3 (naphthalen-2-yl)urea-(7d)
Yield 85 %; 1H NMR (DMSO-d6, 400 MHz) δ 1.69 (s, 6H), 2.21 (s, 3H), 6.81 (s, 1H),
7.35-7.50 (m, 6H), 7.72 - 7.80 (m, 4H), 8.05 (s, 1H), 8.70 (s, 1H), 11.22 (s, 1H); 13C NMR
(DMSO-d6, 100 MHz) δ 12.40, 30.32, 54.90, 112.75, 119.86, 122.49, 124.11, 124.16,
125.93, 126.85, 127.37, 128.00, 128.74, 128.90, 129.26, 134.48, 137.32, 138.70, 149.12,
153.77, 154.66; ESI-HRMS for C22H24N3O2 (M+H)+ calcd. 362.1869, found 362.1872.
(E)-1-(2-(3-(1-(Hydroxyimino)ethyl)phenyl)propan-2-yl)-3 (quinolin-7-yl)urea (7e)
mp 164-166 °C; Yield 85 %; 1H NMR (pyridine-d5, 400 MHz) δ 1.68 (s, 6H), 2.28 (s, 3H),
6.99-7.02 (m, 2H), 7.25 (t, J = 8 Hz, 1H), 7.53 -7.62 (m, 3H), 7.88 (t, J = 9.6 Hz, 2H), 8.16
(s, 1H), 8.63 (s, 1H), 8.77 (d, J = 1.6 Hz, 1H), 9.54 (s, 1H); 13C NMR (DMSO-d6, 100
MHz) δ 12.41, 30.29, 55.03, 113.61, 119.70, 120.20, 122.50, 123.78, 124.22, 125.93,
128.77, 129.01, 136.04, 137.35, 142.06, 148.97, 149.4, 151.29, 153.77, 154.47; ESI-HRMS
for C21H23N4O2 (M+H)+ calcd. 363.1821, found 363.1825.
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General procedure for the preparation of alkoxy oxime derivatives 8: Exemplified for the
preparation of (E)-2-chloro-5-(3-(2-(3-(1-(methoxyimino)ethyl)phenyl)propan-2-
yl)ureido)benzamide (8b)
Methoxyamine hydrochloride (30 mg, 0.362 mmol) was added to a solution of 6b (100 mg,
0.302 mmol) in 3 mL of pyridine. The reaction solution was heated to 90 °C for 2 h and then
the pyridine was removed by evaporation under reduced pressure. The residue was dissolved
in methanol and purified by column chromatography eluting with methanol/chloroform to
obtained 8b (99 mg, 82%). 1H NMR (CDCl3, 400 MHz) δ 1.55 (s, 6H), 2.12 (s, 3H), 3.91 (s,
3H), 6.18 (s, 1H), 6.59 (s, 1H), 6.86 (s, 1H), 7.06 (d, J = 8.8 Hz, 1H), 7.15 (s, 1H), 7.25 (d, J
= 6.8 Hz, 1H), 7.33 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 7.6 Hz, 2H), 7.67 (1H, s), 7.97 (s,
1H); 13C NMR (CDCl3, 100 MHz) δ 13.29, 30.23, 54.97, 62.17, 117.68, 119.75, 121.42,
122.77, 124.49, 126.46, 128.83, 130.33, 136.30, 137.89, 139.93, 149.10, 154.43, 155.037,
168.88; ESI-HRMS for C20H24N4O3Cl (M+H)+ calcd. 403.1537, found 403.1532.
(E)-1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(2-(3-(1-(methoxyimino)ethyl)phenyl)propan-2-
yl)urea (8a)
1H NMR (DMSO-d6, 400 MHz) δ 1.62 (s, 6H), 2.1 (s, 3H), 3.90 (s. 3H), 6.84 (s, 1H), 7.36
(dd, J1 = 7.6 Hz, J2 = 1.6 Hz, 1H), 7.43-7.48 (m, 3H), 7.52 (dd, J1 = 8.8 Hz, J2 = 1.6 Hz),
7.67 (s, 1H), 8.01 (s. 1H), 8.93 (s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 12.80, 29.86,
55.30, 62.04, 117.77, 117.82, 117.88, 122.29, 122.87, 124.88, 124.93, 125.63, 128.82,
131.77, 136.96, 137.96, 147.31, 154.63, 154.91; ESI-HRMS for C20H22N3O2F3Cl (M+H)+
calcd. 428.1353, found 428.1353.
(E)-1-(2-(3-(1-(Methoxyimino)ethyl)phenyl)propan-2-yl)-3 (naphthalen-2-yl)urea (8c)
Yield 58%; 1H NMR (DMSO-d6, 400 MHz) δ 1.65 (s, 6H) 2.19 (s, 3H), 3.90 (s, 3H), 6.78
(s, 1H), 7.30-7.42 (4H, m), 7.48 (d, J = 7.2 Hz, 2H), 7.68-7.72 (m, 2H), 7.76 ( d, J = 8.4 Hz,
2H), 8.00 (s, 1H), 8.67 (s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 13.30, 30.30, 54.91,
62.16, 112.8, 119.9, 122.8, 124.1, 124.4, 126.5, 126.8, 127.3, 128.0, 128.83, 128.89, 129.28,
134.47, 136.29, 138.68, 149.28, 154.71, 155.06; ESI-HRMS for C23H26N3O2 (M+H)+
calcd. 376.2025, found. 376.2026.
Preparation of (E)-1-(2-(3-(1-((2-aminoethoxy)imino)ethyl)phenyl)propan-2-yl)-3 (4-chloro-3-
nitrophenyl)urea (9)
(E)-1-(4-Chloro-3-nitrophenyl)-3-(2-(3-(1-(hydroxyimino)ethyl)phenyl)propan-2-yl)urea
(7b, 100 mg, 0.25 mmol) in 3 mL dry DMF was added drop wise at 0 °C to sodium hydride
dispersion in mineral oil (15.3 mg, 0.50 mmol). The resulting mixture was stirred at 0 °C for
30 min. 2-Chloroethylamine hydrochloride (29.6 mg, 0.25 mmol) in 2 mL DMF was added
and the reaction mixture was stirred at room temperature for 2 h and then the volatiles were
removed under reduced pressure. The residue was dissolved in a minimal amount of
methanol and purified by column chromatography using methanol/chloroform to obtained 9
(49 mg, 46 % ) 1H NMR (DMSO-d6, 400 MHz) δ 1.61 (s, 6H), 2.19 (s, 3H), 2.79 (t, J = 5.6
Hz, 2H), 4.05 (t, J = 5.6 Hz, 2H), 6.95 (s, 1H), 7.34 (t, J = 7.6 Hz, 1H), 7.42-7.47 (m, 3H),
7.56 (d, J = 8.8 Hz, 1H), 7.65 (s, 1H), 8.20 (d, J = 2 Hz, 1H), 9 (s, 1H); 13C NMR (DMSO-
d6, 100 MHz) δ 13.3, 30.1, 41.6, 55.4, 76.6, 113.8, 116.2, 122.7, 122.9, 124.5, 126.3, 128.8,
132.2, 136.5, 141.1, 148.1, 148.8, 154.2, 154.9; ESI-HRMS for C20H24Cl N5O4 (M+H)+
calcd. 434.1595, found. 434.1595.
1-(4-chlorophenyl)-3-(2-(3-(1-hydroxyethyl)phenyl)propan-2-yl)urea (10)
A solution of 1-(2-(3-acetylphenyl)propan-2-yl)-3-(4-chlorophenyl)urea (25 mg, 0.07 mmol)
in THF was cooled in an ice bath to 0 °C. Lithium aluminum hydride solution (2M in THF,
0.8 equiv) was added drop wise over 5 min and then the reaction was continued for
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approximately 1 h at 0 °C until starting material disappeared. The reaction was carefully
quenched with a solution of sodium sulfate. The reaction mixture was filtered through a
sintered funnel and the supernatant washed with dichloromethane. Combined organic
fractions were concentrated under reduced pressure. The residue was purified by column
chromatography using chloroform-methanol as a eluent to give 10 (19 mg, 74%). 1H NMR
(DMSO-d6, 400 MHz) δ 1.25 (d, J = 6 Hz, 3H), 1.54 (s, 6H), 4.64 (pent, J = 4.4 Hz, 1H),
5.09 (d, J = 4 Hz, 1H), 6.56 (s, 1H), 7.11-7.19 (m, 5H), 7.28 (s, 1H), 7.31 (d, J = 9.2 Hz,
1H), 8.51 (s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 26.78, 30.33, 30.44, 55.06, 68.94,
119.47, 122.42, 123.70, 124.88, 128.28, 129.10, 140.18, 147.68, 148.65, 154.48; ESI-HRMS
for C18H22N2O2Cl (M+H)+ calcd. 333.1370, found 333.1378.
1-(2-(3-Isopropylphenyl)propan-2-yl)-3-(naphthalen-2-yl)urea (11)
A solution of 1-(naphthalen-2-yl)-3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea (5o, 25
mg, 0.072 mmol) in methanol (3 mL) containing a catalytic amount of 10% Pd/C was placed
under an atmosphere of hydrogen. After 1h the reaction mixture was filtered through a short
silica gel column and concentrated to give 11 (24 mg, 98%).1H NMR (DMSO-d6, 400 MHz)
δ 1.17 (d, J = 4.4 Hz, 6H), 1.60 (s, 6H), 2.84 (hept, J = 6.8 Hz, 1H), 6.66 (s, 1H), 7.03-7.36
(m, 7H), 7.66 (d, J = 8 Hz, 1H), 7.75 (d, J = 8 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ
24.69, 30.42, 34.26, 55.09, 122.75, 118.22, 119.91, 123.01, 123.58, 124.08, 124.31, 126.84,
127.36, 128.01, 128.59, 128.87, 129.25, 134.49, 138.80, 149.00, 154.78; ESI-HRMS for
C23H27N2O (M+H)+ calcd. 347.2123, found 347.2126.
2-(3-Acetylphenyl)propanenitrile (13)
Thionyl chloride (10 mL) was added at 0 °C to 3-(1-cyanoethyl)benzoic acid (12, 500 mg,
2.85 mmol). The reaction mixture was heated at 80 °C for 2 h. The excess thionyl chloride
was removed to give 3-(1-cyanoethyl)benzoyl chloride, which was used without further
purification.
Next, to a solution of Meldrum’s acid (408 mg, 2.84 mmol) in dichloromethane (15 mL) at 0
°C was added pyridine (0.457 mL, 5.68 mmol). The resulting mixture was stirred for 15 min
and then 3-(1-cyanoethyl)benzoyl chloride (482.5 mg, 2.5 mmol) was added. The reaction
mixture was stirred at 0 °C for 30 min and then for 1h at room temperature. The reaction
mixture was diluted with dichloromethane and washed with 1N HCl. The organic layer was
dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure.
The crude product was dissolved in AcOH-H2O (1:2) and heated at reflux for 4 h. The
reaction mixture was diluted with water and extracted with ethyl acetate (3 × 30 mL). The
combined organic extracts were washed with NaHCO3 solution and brine, then dried over
anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by
column chromatography using hexane-ethyl acetate (9:1) as eluent to give 13 (138 mg,
28%).1H NMR (CDCl3, 400 MHz) δ 1.68 (d, J = 7.2 Hz 3H), 2.63 (s, 3H), 3.99 (q, J = 7.2
Hz, 1H), 6.60 (d, J = 7.6 Hz, 1H), 7.53 (d, J = 2.8 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.91 (t,
J = 2 Hz, 1H), 7.94 (s, 1H).
2-(3-Acetylphenyl) propanoic acid (14)
To a solution of 13 (100 mg, 0.57 mmol) in 2 mL of 1, 4-dioxane was added conc. HCl (1.5
mL) and then the resulting mixture was refluxed for 5 h. After the mixture was allowed to
cool to room temperature, the volatiles were removed under reduced pressure. The residue
was diluted with water (10 mL) and extracted with dichloromethane (3 × 10 mL). The
organic extracts were combined, washed with brine (2 × 10 mL), dried over anhydrous
magnesium sulfate, filtered and concentrated to give 14 as a white solid (86 mg, 78%
yield). 1H NMR (CDCl3, 400 MHz) δ 1.57 (d, J = 7.2 Hz, 3H), 2.38 (s, 3H), 3.83 (q, J = 7.2
Hz, 1H), 7.42-7.50 (m, 2H), 7.61 (d, J = 7.6 Hz, 1H), 7.75 (s, 1H).
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2-(3-Acetylphenyl)propanoyl azide (15)
Thionyl chloride (2 mL) was added to 14 (86 mg, 0.40 mmol) at 0 °C. The mixture was then
heated at 80 °C for 2 h. The reaction mixture was concentrated under reduced pressure. The
resulting acid chloride was used without further purification.
A solution of the acid chloride (84 mg, 0.40 mmol) in 3 mL dry acetone was added to a
solution of sodium azide (325 mg, 5 mmol) in 2 mL of water at 0 °C over 10 min. The
reaction mixture was stirred for 2 h at 25 °C, and then poured into ice and extracted with
ether (2 × 10 mL). The organic extracts were combined, washed with brine, dried over
anhydrous MgSO4, filtered and concentrated to give acyl azide 15, which was used without
further purification.
1-(3-(1-Isocyanatoethyl)phenyl) ethanone (16)
Acyl azide 15 (80 mg, 0.42 mmol) was refluxed in benzene (5 mL) of 1.5 h and then the
solvent was removed under vacuum to give isocyanate 16 in quantitative yield, which was
used without further purification.
1-(1-(3-Acetylphenyl)ethyl)-3-(4-chlorophenyl)urea (17)
Compound 17 (71%) was prepared following the general procedure for 6. 1H NMR (DMSO-
d6, 400 MHz) δ 1.35 (d, J = 6.8 Hz, 3H), 2.55 (s, 3H), 4.95 (pent, J = 6.8 Hz, 1H), 5.68 (d, J
= 7.2 Hz, 1H), 7.12-7.17 (m, 4H), 7.32-7.36 (m, 2H), 7.44 (d, J = 8.0 Hz, 1H), 7.76 (d, J =
7.6 Hz, 1H), 7.84 (s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 23.20, 26.97, 49.77, 120.94,
124.96, 127,84, 128.14, 129.14, 129.16, 131.40, 137.47, 137.58, 145.23, 155.23, 199.09;
ESI-HRMS for C17H18N2O2Cl (M+H)+ calcd. 317.1057, found 317.1060.
3-(2-Methyl-1,-3-dioxolan-2-yl)benzonitrile (19)
To the mixture of ethylene glycol (0.22 mL, 4 mmol), 3-acetylbenzonitrile 18 (300 mg, 2.04
mmol) and benzene (10 mL) in a Dean-Stark apparatus was added a catalytic amount of p-
TSA (0.1 equiv). The reaction mixture was heated at 110 °C for 4 h. The benzene was
removed under reduced pressure and the residue was purified by column chromatography
using ethylacetate-hexane as an eluent to give 19 (293 mg, 76%). 1H NMR (CDCl3, 400
MHz) δ 2.62 (s, 4H), 7.59 (t, J = 7.6 Hz, 1H), 7.82 (d, J = 7.6 Hz, 1H)), 8.15 (d, J = 8 Hz,
1H), 8.21 (s, 1H).
3-(2-Methyl-1,3-dioxolan 2 yl)phenylmethanamine (20)
A solution of cyano ketal 19 (290 mg, 1.53 mmol) in dry THF (10 mL) was cooled to 0 °C
under a nitrogen atmosphere. Then a solution of 2M lithium aluminum hydride (3 mmol) in
THF was added over a 10-min period. The reaction mixture was stirred for 1.5 h and then
ethyl acetate was added followed by slow addition of water to decompose the excess LAH.
The reaction mixture was concentrated under reduced pressure. The residue was dissolved in
chloroform, washed with brine, dried over anhydrous MgSO4, filtered and concentrated. The
residue was purified by column chromatography using chloroform and methanol as an
eluent to give 20 (176 mg, yield 60%). 1H NMR (CDCl3, 400 MHz) δ 1.66 (s, 3H), 3.79 (t, J
= 6 Hz, 2H), 3.88 (s, 2H), 4.04 (t, J = 6 Hz, 2H), 7.24-7.42 (m, 4H).
4-Nitrophenyl-3-(2-methyl-1,3-dioxolan 2 yl)benzylcarbamate (21)
To a solution of benzylamine 20 (176 mg, 0.911 mmol) and N,N-diisopropylethylamine
(313 cL, 1.8 mmol) in 4 mL of 1:1 CH2Cl2/THF was added a solution of 4-
nitrophenylchloroformate (366 mg, 1.82 mmol) in 2 mL of 1:1 CH2Cl2/THF. After stirring
the reaction mixture at room temperature for 24 h, it was diluted with dichloromethane and
washed sequentially with saturated NaHCO3, water and brine. The organic layer was dried
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over anhydrous MgSO4, filtered and concentrated. The residue was purified by column
chromatography eluting with ethylacetate/hexane to give 21 (267 mg, 82%).
1-(4-Chlorophenyl)-3-(3-(2-methyl-1,3-dioxolan-2-yl)benzyl)urea (22)
4-Nitrophenyl-N-benzylcarbamate 21 (267 mg, 0.767 mmol) was added to a solution of 4-
chloroaniline (97 mg, 0.767 mmol) and triethylamine in dichloromethane (5 mL). The
mixture was stirred at room temperature until starting materials were consumed. The
reaction mixture was then diluted with dichloromethane (50 mL) and washed with aq.
NaOH, water and brine. The organic layer was dried over anhydrous MgSO4, filtered and
concentrated The residue was purified by column chromatography eluting with methanol/
chloroform to give 22 (165 mg, 71%). 1H NMR (CDCl3, 400 MHz) δ 1.58 (s, 3H), 3.71 (t, J
= 6.8 Hz, 2H), 3.99 (t, J = 6.8 Hz, 2H), 4.36 (d, J = 5.6 Hz, 2H), 6.78 (s, 1H), 7.16-7.18 (m,
4H), 7.23 - 7.26 (m, 1H), 7.35 (d, J = 5.6 Hz, 2H).
1-(3-Acetylbenzyl)-3-(4-chlorophenyl) urea (23)
A 2N HCl solution was added to a solution of 22 (165 mg, 0.479 mmol) in THF (2 mL). The
mixture was refluxed for several hours until the starting materials were consumed. The
reaction mixture was allowed to cool to room temperature, quenched with solid NaHCO3,
and then the volatiles were removed under reduced pressure. The residue was diluted with
ethyl acetate and then washed with water. The organic layer was dried over anhydrous
MgSO4, filtered and concentrated. The residue was purified by chromatography to give 23
(144 mg, 100%)1H NMR (DMSO-d6, 400 MHz) δ 4.44 (d, J = 5.6 Hz, 2H), 5.37 (t, J = 3.7
Hz, 1H), 6.83 (s, 1H), 7.20-7.26 (5H, m), 7.40 (t, J = 7.6 Hz, 1H), 7.50 (d, J = 7.2 Hz, 1H),
7.82 (d, J = 7.6 Hz, 1H), 7.85 (s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 27.45, 43.13,
119.85, 125.21, 127.11, 127.59, 129.13, 129.37, 132.61, 137.49, 140.07, 141.68, 155.73,
198.58; ESI-HRMS for C16H16N2O2Cl (M+H)+ calcd. 303.0900, found 303.0907.
3-Acetyl-α, α-dimethylbenzylamine (24)
3-Acetyl-α, α-dimethylbenzyl isocyanate 3 (1000 mg, 4.92 mmol) in 8N HCl (30 mL) were
refluxed for 30 min. The reaction mixture was cooled to 0 °C and then washed with diethyl
ether. The aqueous portion was neutralized with a 10% NaOH solution and extracted with
diethyl ether (3 × 20 mL). The combined organic layers were washed with brine, dried over
anhydrous MgSO4, filtered and concentrated. The residue was purified by chromatography
eluting with methanol/chloroform to give 24 as a yellow oil (478 mg, 55%). 1H NMR
(CDCl3, 400 MHz) δ 1.57 (s, 6H), 2.61 (s, 3H), 3.72 (s, 2H), 7.43 (t, J = 7.6 Hz, 1H), 7.75
(d, J = 7.6 Hz, 1H), 7.82 (d, J =7.6 Hz, 1H), 8.14 (s, 1H).
4-Chlorophenyl (2-(3-acetylphenyl)propan-2-yl)carbamate (25)
4-Chlorophenyl chloroformate (317 cL, 2.24 mmol) in dichloromethane (2 μL) was added to
a mixture of 3-acetyl-α, α-dimethylbenzylamine 24 and diisopropylethylamine (390 μL,
2.24 mmol). The reaction mixture was stirred for 2 h. It was then diluted with
dichloromethane, washed with 1N HCl, and then brine. The organic layer was dried over
anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by
column chromatography using hexane/ethyl acetate as eluent to give 25 (594 mg, 81%). 1H
NMR (CDCl3, 400 MHz) δ 1.73 (s, 6H), 2.60 (s, 3H), 5.65 (s, 1H), 7.02 (d, J = 8.4 Hz, 1H),
7.25 (d, J = 6 Hz, 2H), 7.44 (t, J = 8 Hz, 1H), 7.65 (d, J = 7.6 Hz, 1H), 7.82 (d, J = 7.6 Hz,
1H), 8.07 (1H, s); 13C NMR (DMSO-d6, 100 MHz) δ 27.45, 29.79, 55.50, 124.23, 124.55,
127.31, 129.28, 129.55, 129.79, 130.39, 137.30, 148.70, 150.32, 152.97, 198.64; ESI-HRMS
for C18H19NO3Cl (M+H)+ calcd. 332.1053, found 332.1059.
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N-(2-(3-Acetylphenyl)propan-2-yl)-2-(4-chlorophenyl)acetamide (26)
4-Chlorophenylacetylchloride (106 mg, 0.56 mmol) in dichloromethane was added to a
solution of 3-acetyl-α, α-dimethylbenzylamine 24 (100 mg, 0.56 mmol) and triethylamine
(120 μL, 0.86 mmol) in dichloromethane over a period of 5 to 10 min at 0 °C. The reaction
mixture was stirred at room temperature for 2 h. The mixture was diluted with
dichloromethane (20 mL) and washed with 1N HCl, water and brine. The organic layer was
dried over anhydrous MgSO4, filtered and concentrated. The residue was purified by column
chromatography using hexane/ethyl acetate as eluent to give 26 (146 mg, 80%). 1H NMR
(CDCl3, 400 MHz) δ 1.61 (s, 6H), 2.53 (s, 3H), 3.46 (s, 2H), 5.68 (s, 1H), 7.19 (d, J = 7.2
Hz, 2H), 7.30-7.38 (m, 3H), 7.46 (d, J = 8 Hz, 1H), 7.75 (d, J =7.2 Hz, 1H), 7.87 (s,
1H); 13C NMR (DMSO-d6, 100 MHz) δ 27.26, 29.89, 42.54, 55.34, 124.71, 126.76, 128.74,
128.98, 130.23, 131.45, 131.63, 136.22, 137.19, 148.96, 169.54, 198.59; ESI-HRMS for
C19H21NO2Cl (M+H)+ calcd. 330.1261, found 330.1270.
3-Acetyl-α, α-dimethylbenzylalcohol (27)
A solution of 3-acetyl-α α-dimethylbenzylamine (500 mg, 2.82 mmol) in chloroform was
cooled to 0 °C. Chlorosulfonic acid (109 mg, 0.94 mmol) was added drop wise over a period
of 15 min. During this time a white precipitate formed. Stirring was continued for another 10
min. The reaction mixture was filtered to yield the corresponding substituted N-
benzylsulfonic acid (253 mg, 70% with respect to chlorosulfonic acid), which was used
without further purification.
The N-benzylsulfonic acid (169 mg, 0.658 mmol) was suspended in 2 mL of water and then
KNO2 (168 mg, 1.97 mmol, 3 equiv) was added. An almost clear solution was immediately
formed. To this solution was added 2 mL sulfate buffer (pH = 2.8) and the resulting mixture
was stirred for 2 hours. The reaction mixture was diluted with 4 mL water and extracted
with ethyl acetate (3 × 10 mL). The combined organic layers were washed with water. The
organic layer was dried over anhydrous MgSO4, filtered and concentrated. The residue was
purified by column chromatography eluting with ethyl acetate/hexane to obtained 26 (26
mg, ~30%). 1H NMR (CDCl3, 400 MHz) δ 1.55 (s, 6H), 2.55 (s, 3H), 7.37 (t, J = 8 Hz, 1H),
7.66 (d, J = 7.2 Hz, 1H), 7.76 (d, J = 7.6 Hz, 1H), 8.04 (s, 1H). 13C NMR (CDCl3, 400
MHz) δ 26.9, 31.9, 72.5, 124.4, 126.9, 128.6, 129.6, 137.1, 150.0, 198.8.
2-(3-Acetylphenyl) propan-2-yl (4-chlorophenyl)carbamate (28)
To a solution of 3-acetyl-α, α-dimethylbenzylalcohol (27, 21 mg, 0.117 mmol) in 2 mL dry
benzene was added 4-chlorophenyl isocyante, followed by 17 μL triethyamine. The reaction
mixture was heated to 70 °C for 3 h. The reaction mixture was allowed to cool to room
temperature and then diluted with ethyl acetate (20 mL), washed with 1N HCl, brine and
water. The organic layer was dried over anhydrous magnesium sulfate, filtered and
evaporated. The residue was purified by column chromatography eluting with ethyl acetate/
hexane yielding 28 (23 mg, 62%). 1H NMR (CDCl3, 400 MHz) δ 1.84 (s, 6H), 2.60 (s, 3H),
6.71 (s, 1H), 7.20 (d, J = 8.8 Hz, 2H), 7.27 (d, J = 8.4 Hz, 2H), 7.45 (t, J = 8.0 Hz), 7.62 (d, J
= 7.6 Hz, 1H), 7.84 (d, J = 7.6 Hz, 1H), 8.02 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 26.96,
29.08, 81.73, 119.8, 127.74, 128.90, 129.15, 129.26, 129.92, 136.67, 137.39, 146.71,
151.89, 198.29; ESI-HRMS for C18H18ClNO3 (M+Na)+ calcd. 354.0873, found 354.0872.
3-Phenyl α, α-dimethylbenzylamine (30)
To a room temperature stirring solution of 3-cyanobiphenyl (200 mg, 1.11 mmol) in 5 mL of
diethyl ether was added 1M methylmagnesium bromide in butyl ether (3.33 mmol). The
reaction mixture was stirred for 30 min and then 326 μL (1.11 mmol) of (i-PrO)4Ti was
added. The solution became dark-brown and was stirred overnight before being treated with
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10% solution NaOH (4 mL). The suspension was filtered to remove precipitated inorganic
material, which washed with dichloromethane. The organic layer was separated and the
aqueous layer was extracted with dichloromethane. The combined organic solutions were
washed with water, brine and then dried over anhydrous MgSO4, filtered and evaporated to
dryness. The residue was purified by column chromatography eluting with methanol/
chloroform to give 30 (133 mg, 57%). 1H NMR (CDCl3, 400 MHz) δ 1.57 (s, 6H), 2.61 (bs,
2H), 7.34 -7.50 (m, 6H), 7.60 (d, J =7.2 Hz, 2H), 7.73 (s, 1H); 13C NMR (CDCl3, 400 MHz)
δ 32.7, 53.0, 123.97, 123.98, 125.4, 127.4, 127.5, 128.9, 141.4, 141.7, 150.4.
3-Phenyl α-cyclopropylbenzylamine (31)
Ethyl magnesium bromide (3M) in diethyl ether (1.841 mmol, 2.2 eq.) was added at −78 °C
to a solution of 3-cyanobiphenyl (150 mg, 0.838 mmol) and Ti(Oi-Pr)4 (0.269 mL, 0.920
mmol) in 5 mL of Et2O. The yellow solution was stirred for 10 min and then the solution
was allowed to warm to room temperature and continued to be stirred for 1 h before
BF3•OEt2 (0.206 mL, 1.76 mmol) was added. Stirring was continued for an additional hour.
The reaction mixture was quenched with 3 mL of 1 N HCl and then washed with ether (15
mL). The aqueous layer was basified with 10% NaOH (10 mL) and extracted with diethyl
ether. The organic layer was dried over anhydrous MgSO4, filtered and concentrated under
reduced pressure. The residue was purified by column chromatography on silica gel eluting
with methanol/chloroform to yield 31 (98 mg, 52%). 1H NMR (CDCl3, 400 MHz) δ 1.1 (t, J
= 4 Hz, 2H), 1.04 (t, J = 4 Hz, 2H), 7.25 -7.79 (m, 1H), 7.35-7.46 (m, 5H), 7.52 (s, 1H), 7.58
(d, J = 7.2 Hz,1H).
4-Nitrophenyl(2-([1, 1′-biphenyl]-3-yl) propan-2-yl)carbamate (33)
Prepared following the same procedure as 21. Yield 71%. 1H NMR (CDCl3, 400 MHz) δ
1.62 (s, 6H), 6.81 (d, J = 8.8 Hz, 2H), 7.26-7.66 (m, 10H), 8.11 (d, J = 8.8 Hz, 2H).
4-Nitrophenyl(1-([1,1′-biphenyl]-3-yl)cyclopropyl)carbamate (34)
Prepared following the same procedure as 21. Yield 68%. 1H NMR (CDCl3, 400 MHz) δ
1.39-1.40 (m, 2H), 1.42-1.45 (m, 2H), 6.89 (d, J = 9.2 Hz, 2H), 7.31-7.49 (m, 6H), 7.54-7.58
(m, 3H), 8.16 (d, J = 9.2 Hz, 2H).
4-Nitrophenyl (2-phenylpropan-2-yl)carbamate (35)
Prepared folloeing the same procedure as 21. Yield 62%. 1HNMR (CDCl3, 400 MHz) δ
1.73 (s, 6H), 5.6 (bs, 1H), 6.79 (d, J = 8.8 Hz, 2H), 7.23-7.25 (m, 2H), 7.34 (t, J = 7.6 Hz,
1H), 8.09 (d, 2H, J = 9.2 Hz), 8.16 (d, J = 8.8 Hz, 1H).
5-(3-(2-([1, 1′-biphenyl]-3-yl) propan-2-yl)ureido)-2-chlorobenzamide (36a)
Prepared following the same procedure as 22. Yield 45%; 1H NMR (CDCl3, 400 MHz) δ
1.74 (s, 6H), 5.63 (s, 1H), 5.96 (s, 1H), 6.62 (s, 1H), 7.18 (d, J = 8.8 Hz, 1H), 7.28 (d, J =
2.4, 1H), 7.31-7.35 (m, 1H), 7.39 -7.48 (m, 6H), 7.55 (d, J = 7.2 Hz, 2H), 7.68 (s, 1H), 7.77
(d, J = 8.8 Hz, 1H); 13C NMR (CD3OD, 100 MHz) δ 29.1, 54.9, 118.3, 120.6, 122.8, 123.4,
123.7, 124.8, 126.8, 127.0, 128.5, 130.1, 132.5, 136.0, 141.3, 141.6, 155.1, 171.0; ESI-
HRMS for C23H23N3O2Cl (M+H)+ calcd. 408.1479, found 408.1485.
1-(2-([1,1′-Biphenyl]-4-yl)propan-2-yl)-3-(4-chlorophenyl)urea (36b)
Synthesized following the synthetic procedure in scheme 6 starting with 4-
phenylbenzonitrile. Yield 68%; 1H NMR (CDCl3, 400 MHz) δ 1.73 (s, 6H), 5.53 (s, 1H),
6.76 (d, J = 8.8 Hz, 1H), 7.18 (s, 1H), 7.23 (d, J= 8.8 Hz, 1H), 7.28 (d, J = 7.2 Hz, 1H),
7.35-7.38 (m, 2H), 7.45 -7.53 (m, 6H), 8.06 (d, J = 8.8 Hz, 1H), 8.14 (d, J = 8.4 Hz,
Gorla et al. Page 16
J Med Chem. Author manuscript; available in PMC 2013 September 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
1H); 13C NMR (DMSO-d6, 100 MHz) δ 30.28, 54.79, 116.49, 119.52, 126.07, 126.89,
126.99, 127.18, 129.11, 129.58, 138.48, 140.02, 140.66, 148.20, 154.48; ESI-HRMS for
C22H22N2OCl (M+H)+ calcd. 365.1421, found 365.1428.
5-(3-(1-([1,1′-Biphenyl]-3-yl)cyclopropyl)ureido)-2-chlorobenzamide (37)
Prepared following the same procedure as 22. Yield 62%; 1H NMR (DMSO-d6, 400 MHz) δ
1.23 (t, 2H, J = 6.8 Hz), 1.30 (t, 2H, J = 8 Hz), 7.22 (d, J = 7.2 Hz, 2H), 7.28 (d, J = 8.8 Hz,
1H), 7.35-7.47 (m, 5H), 7.53 ( t, J = 2.4 Hz, 2H), 7.61 (d, J = 7.6 Hz, 2H), 7.80 (s, 1H), 8.70
(s, 1H), 8.70 (s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 19.2, 34.9, 118.1, 121.6, 123.7,
124.6, 124.8, 127.0, 127.4, 128.0, 129.3, 129.5, 130.3, 137.8, 139.8, 140.7, 141.1, 145.5,
155.5, 168.8; ESI-HRMS for C23H20N3O2Cl (M+H)+ calcd. 406.1322, found 406.1323.
1-(2-Oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-3-(2-phenylpropan 2 yl)urea (38)
1.52 (s, 6H), 6.38 (d, J = 6 Hz, 1H), 6.56 ( t, J = 7.2 Hz, 1H), 6.66 (t, J = 7.2 Hz, 1H),
7.10-7.15 (m, 2H), 7.21-7.25 (m, 2H), 7.31-7.33 (m, 2H), 8.16 (s, 1H), 10.26 (s, 1H), 10.35
(s, 1H) ); 13C NMR (DMSO-d6, 100 MHz) δ 30.4, 54.8, 94.6, 99.9, 108.9, 110.7, 124.5,
125.4, 126.4, 128.5, 130.4, 134.8, 149.2, 154.8, 156.1; ESI-HRMS for C17H18N4O2 (M+H)+
calcd. 311.1508, found 311.1511.
Biological assays
Determination of IC50 values—Inhibition of recombinant CpIMPDH, purified from E.
coli,12 was assessed by monitoring the production of NADH by fluorescence at varying
inhibitor concentrations (25 pM - 5 cM). IMPDH was incubated with inhibitor for 5 min at
room temperature prior to addition of substrates. The following conditions were used: 50
mM Tris-HCl, pH 8.0, 100 mM KCl, 3 mM EDTA, 1 mM dithiothreitol (assay buffer) at 25
°C, 10 nM CpIMPDH, 300 VM NAD and 150 VM IMP. To characterize the non-specific
binding of inhibitors, assays were also carried out in the presence of 0.05% BSA (fatty acid
free). IC50 values were calculated for each inhibitor according to Equation 1 using the
SigmaPlot program (SPSS, Inc.):
(Eq.1)
where νi is initial velocity in the presence of inhibitor (I) and νo is the initial velocity in the
absence of inhibitor. Inhibition at each inhibitor concentration was measured in
quadruplicate and averaged; this value was used as νi. The IC50 values were determined
three times; the average and standard deviations are reported.
Determination of antiparastic activity—Antiparasitic activity was tested by
monitoring the growth of a of T. gondii strain (Toxo/CpIMPDH) that relies on CpIMPDH.
Wild-type T. gondii (Toxo/WT) relies on a eukaryotic IMPDH that should be resistant to
CpIMPDH inhibitors. Both parasites express yellow fluorescent protein, which allows
growth to be easily monitored. Parasites were cultured on hTERT immortalized human
foreskin fibroblasts cells in 96 well plates and fluorescence was measured daily with a
SpectraMax M22/M2e (Molecular Devices) plate reader (Ex 485, Em 530) for 6-7 days.
Growth inhibition was calculated on a day within the exponential growth phase21.
Stability assays—Mouse microsomal and plasma stability experiments were performed
by Cyprotex Discovery (Watertown, MA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Cp Cryptosporidium parvum
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Figure 1.
CpIMPDH inhibitor identified by HTS.
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Scheme 1.
IMPDH catalyzed conversion of IMP to XMP. R5P = ribose-5′-phosphate
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Scheme 2.
General procedure for preparation of urea derivatives.*
*Reagents and conditions: (a) (i) O3, DCM, -78 °C; (ii) Me2S, 10 h, 58%; (b) DCM, R-
PhNH2 (4), 2-4 h, 70-85%; (c) THF, R-PhNH2 (4), 6 h, 70 0C, 70-75%; (d) NH OH•HCl,
pyridine, 2 h, 90 °2 C, 80-85%; (e) NH2OMe•HCl, pyridine, 2 h, 90 oC, 60-85 %; (f) (i)
NaH, THF, 0 oC, 30 min; (ii) Cl(CH ) o2 2NH2•HCl, rt, 10 h, 53%; (g) LAH, THF, 1 h, 0 C,
74%; (h) H2/Pd-C, MeOH, 1 h, 90%.
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Scheme 3.
Preparation of mono-methyl derivative 17.*
*Reagents and conditions (a) (i) SOCl , reflux, 2 h; (ii) Meldrum’s acid, pyridine, DCM, 0-5
° 2 C, 2 h; iii) AcOH, H2O, reflux, 4 h, 28%; (b) Conc. HCl, 1,4-dioxane, reflux, 2 h, 78%;
(c) (i) SOCl2, reflux; (ii) NaN3, DCM; (d) benzene, reflux, 1.5 h, 92%; (e) 4-Cl-PhNH2,
THF, reflux, 6 h, 70%.
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Scheme 4.
Preparation of benzyl derivative 23.*
*Reagents and conditions (a) (CH2OH)2, p-TSA, benzene, 4 h, 110 °C, Dean-Stark, 76%;
(b) LAH, ether, 0 °C, 1.5 h, 60%; (c) DIPEA, 4-NO2-PhOCOCl, DCM/THF (1:1), rt, 24 h,
82%; (d) 4-Cl-PhNH2, DCM, rt, 10 h, 71%; (e) 2N HCl, THF, rt, 2 h, 91%.
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Scheme 5.
Preparation of carbamate and amide derivatives.*
*Reagents and conditions (a) 8N HCl, 70 °C, 3 h, 55%; (b) 4-ClPhOCOCl, DIPEA, DCM/
THF, rt, 24 h, 81% ; (c) 4-Cl-PhCH COCl, DCM, 0 °C to rt, 80%; (d) (i) ClSO o2 3H,
CHCl3, 0 C (ii) KNO2 (iii) Water, pH = 2.8, 30%; (e) TEA, benzene, 4-Cl-Ph-NCO, 70 °C,
3 h, 62%.
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Scheme 6.
Preparation of biphenyl derivatives 36, 37 and unsubstituted benzylderivative 38.*
*Reagents and conditions (a) (i) 3 equiv. CH3MgBr, ether, rt, 30 min; (ii) Ti(i-PrO)4, 10 h,
57%; (b) (i) 2 equiv. EtMgBr, Ti(i-PrO)4, -78 °C to rt, 1 h; (ii) 2 equiv. BF3•OEt2, 1 h, 52%;
(c) 4-NO2PhOCOCl, DIPEA, DCM/THF, 10 h; (d) 4-Cl-PhNH2, TEA, DCM, rt, 10 h, 71%.
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Table 1
SAR of the anilide. Assays as described in methods. No significant inhibition of human IMPDH type 2 was
observed (IC50 ≥ 5 μM).
IC50 (nM)
ID R (−) BSA (+) BSA
5a Ph 250 ± 20 410 ± 20
5b 4-Cl-Ph 20 ± 7 37 ± 7
5c 4-Br-Ph 10 ± 4 20 ± 10
5d 3-Cl-Ph 70 ± 10 330 ± 30
5e 2-Cl-Ph >5000 a n.d.
5f 4-OMe-Ph 9 ± 1 21 ± 7
5g 4-tBu-Ph >5000 a n.d.
5h 3,4-di-ClPh 6 ± 1 50 ± 20
5i 3-CF3-4-Cl-Ph 4 ± 1 20 ± 6
5j 3-OMe,4-Cl-Ph 1.3 ± 0.2 5 ± 1
5k 3-CONH2,4-Cl-Ph 2.3 ± 0.8 3 ± 1
5l 3-CONHCH3,4-Cl-Ph 7 ± 2 14 ± 3
5m 3-CON(Me)2,4-Cl-Ph 8 ± 1 11.7 ± 0.5
5n 3,4-(OCH2CH2O)-Ph 7.2 ± 0.6 110 ± 30
5o 2-Naphthyl 2.1 ± 0.8 40 ± 20
5p 1-Naphthyl >5000 a n.d.
5q 6-Quinolyl 1.8 ± 0.4 4 ± 1
5r 7-Quinolyl 0.8 ± 0.1 6 ± 2
5s 3-Quinoline 70 ± 10 308 ± 8
5t 2-Quinoline 250 ± 20 1100 ± 300
aOne determination. n.d., not determined.
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Table 2
SAR of the isopropenyl substituent.
Compound Structure IC50 (nM)
(−) BSA (+) BSA
38 >5000 n.d.
11 >5000 n.d.
10 80 ± 20 120 ± 10
36a 4 ± 4 14 ± 3
36b >5000a n.d.
6a 39 ± 10b 64 ± 22b
6b 9 ± 5 20 ± 2
6c 54 ± 7 52 ± 4
aOne determination,
b
Two determinations, n.d., not determined.
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Table 3
SAR of the urea moiety.
Compound Structure IC50 (nM)
(−) BSA (+) BSA
17 70 ± 20 110 ± 40
23
~5000a n.d.
37 40 ± 10 90 ± 30
5u 900 ± 400 5000
25 >5000 n.d.
26 >5000 n.d.
28 90 ± 20 120 ± 10
aOne determination,
b
n.d., not determined.
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Table 4
SAR of oxime and methyloxime analogs
ID X R IC50 (nM)
(−) BSA (+) BSA
7a N-OH 3-CF3,4-Cl-Ph 1.0 ± 0.1 4 ± 2
7b N-OH 3-NO2,4-Cl-Ph 0.66 ± 0.08 2.0 ± 0.4
7c N-OH 3-CONH2,4-Cl-Ph 5 ± 1 6 ± 2
7d N-OH 2-Naphthyl 1.0 ± 0.2 2.3 ± 0.6
7e N-OH 7-Quinolyl 0.9 ± 0.2 1.2 ± 0.3
8a N-OMe 3-CF3, 4-Cl-Ph 5 ± 1 18 ± 3
8b N-OMe 3-CONH2,4-Cl-Ph 5 ± 2 5 ± 1
8c N-OMe 2-Naphthyl 1.6 ± 0.1 13 ± 4
9 N-O(CH2)2NH2 3-NO2,4-Cl-Ph 20 ± 3.4 24 ± 17
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Table 5
Mouse liver microsome and plasma stability: n.d., not determined.
Compound Mouse Microsomal Stability (t1/2, min) Mouse Plasma Stability (t1/2, min)
5k 25 >120
5r 5.9 >120
6c >700 >120
7a 88 n.d.
7b 11 n.d.
7c 190 >120
7e 45 >120
8a 33 n.d.
9 121 n.d
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Table 6
Antiparasitic activity of selected urea compounds. Assays as described in Methods 21. Unless otherwise stated
all values are the average 3 independent determinations.
Compound
EC50 (μM)
Selectivitya
Toxo/WT Toxo/CpIMPDH
5a 6 ± 4 0.77 ± 0.06 8
5b > 25 0.18 ± 0.02 > 140
5c > 25 0.2 ± 0.01 > 120
5d 0.402 ± 0.002 0.38 ± 0.01 1.0
5g 20 ± 2 b 7.2 ± 0.4 b 3
5h 4 ± 2 0.22 ± 0.04 20
5j 2.3 ± 0.2 b 0.018 ± 0.002 b 127
5k 15 ± 3 0.23 ± 0.04 65
5l 19 ± 6 0.18 ± 0.03 100
5m 9 ± 1 0.09 ± 0.03 100
5n 8 ± 1 0.2 ± 0.2 50
5o > 25 0.20 ± 0.03 > 120
5q 7.6 ± 0.8 0.02 ± 0.01 ≥ 80
5r 3.0 ± 0.1 b < 0.2 > 15
5s 2 ± 1 1.1 ± 0.4 2.3
5t 3 ± 1 3.4 ± 0.3 0.9
6b 3.2 ± 0.7 0.2 ± 0.1 16
6c > 25 0.38 ± 0.05 b > 66
7a 2.7 ± 0.2 0.01 ± 0.01 250
7b 4 ± 2 0.006 ± 0.005 670
7c > 25 1.9 ± 0.6 > 12
7d 5 ± 4 0.08 ± 0.01 63
7e 14 ± 6 0.058 ± 0.003 230
8a 1.4 ± 0.4 0.016 ± 0.008 86
8b >25 0.2 ± 0.1 >120
8c 2.3 ± 0.8 0.013 ± 0.009 180
9 10.1 ± 1.9 0.51 ± 0.007 20
10 19 ± 6 0.9 ± 0.4 20
17 8 ± 4 2.3 ± 0.6 4
23 7 ± 5 11 ± 3 0.6
36a 6 ± 3 0.21 ± 0.09 30
37 9 ± 6 0.6 ± 0.2 15
aSelectivity is the ratio of EC50 Toxo/CpIMPDH to EC50 Toxo/WT.
b
Two determinations.
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